Abstract:Immunization with recombinant glycoprotein-based vaccines is a promising approach to induce protective immunity against viruses. However, the complex biosynthetic maturation requirements of these glycoproteins typically necessitate their production in mammalian cells to support their folding and post-translational modification. Despite these clear advantages, the incumbent costs and infrastructure requirements with this approach can be prohibitive in developing countries, and the production scales and timelines may prove limiting when applying these production systems to the control of pandemic viral outbreaks. Plant molecular farming of viral glycoproteins has been suggested as a cheap and rapidly scalable alternative production system, with the potential to perform post-translational modifications that are comparable to mammalian cells. Consequently, plant-produced glycoprotein vaccines for seasonal and pandemic influenza have shown promise in clinical trials, and vaccine candidates against the newly emergent severe acute respiratory syndrome coronavirus-2 have entered into late stage preclinical and clinical testing. However, many other viral glycoproteins accumulate poorly in plants, and are not appropriately processed along the secretory pathway due to differences in the host cellular machinery. Furthermore, plant-derived glycoproteins often contain glycoforms that are antigenically distinct from those present on the native virus, and may also be under-glycosylated in some instances. Recent advances in the field have increased the complexity and yields of biologics that can be produced in plants, and have now enabled the expression of many viral glycoproteins which could not previously be produced in plant systems. In contrast to the empirical optimization that predominated during the early years of molecular farming, the next generation of plant-made products are being produced by developing rational, tailor-made approaches to support their production. This has involved the elimination of plant-specific glycoforms and the introduction into plants of elements of the biosynthetic machinery from different expression hosts. These approaches have resulted in the production of mammalian N-linked glycans and the formation of O-glycan moieties in planta . More recently, plant molecular engineering approaches have also been applied to improve the glycan occupancy of proteins which are not appropriately glycosylated, and to support the folding and processing of viral glycoproteins where the cellular machinery differs from the usual expression host of the protein. Here we highlight recent achievements and remaining challenges in glycoengineering and the engineering of glycosylation-directed folding pathways in plants, and discuss how these can be applied to produce recombinant viral glycoproteins vaccines.

Recombinant VLP Vaccines Synthesized in Plant Expression Systems: Current Updates and Prospects

Maximizing the Production of Recombinant Proteins in Plants: from Transcription to Protein Stability

N-Glycosylation Modification of Plant-Derived Virus-Like Particles: An Application in Vaccines

Recent advances in expression and purification strategies for plant made vaccines

Platforms, advances, and technical challenges in virus-like particles-based vaccines

A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding

Virus-like Particle Vaccines and Platforms for Vaccine Development

Research progress of transgenic plant-derived vaccines

Virus-like particles as powerful vaccination strategy against human viruses

Advances in influenza virus-like particles bioprocesses

Plant Virus Nanoparticles for Vaccine Applications

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Progress in Developing Virus-Like Particle Influenza Vaccines

Progress in developing virus-like particle influenza vaccines.

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

[Current research status of virus-like particle vaccine]

Recent Advances in Recombinant Pharmaceutical Proteins and Vaccines Production in Chloroplasts

Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery

Plant glycoengineering for designing next-generation vaccines and therapeutic proteins

Virus-like particles: The new frontier of vaccines for animal viral infections

Gene-free Viral-like particles (VLPs) offer a safer alternative to inactivating or weakening viral strains for traditional vaccines. VLP-based vaccinations without adjuvants have been found to promote humoral and cellular immunity